News and Updates

AstraZeneca and Ionis face a setback after Wainua fails to meet primary endpoints in a recent heart disease trial. Learn the clinical and market implications.

Roche has discontinued two late-stage Huntington’s disease drug trials after data failed to show clinical efficacy in lowering toxic huntingtin protein.

AstraZeneca and Ionis end Phase 3 heart disease trial for eplontersen after failing to meet primary endpoints in patients with ATTR-CM.

A new clinical trial reveals that stem cell-derived dopamine cells are safe and effective for treating Parkinson’s disease symptoms. Learn more here.

Fate Therapeutics has received FDA clearance for its FT839 IND application. Learn how this iPSC-derived CAR-NK therapy is shaping the future of oncology.

MAIA Biotechnology shares positive Phase II results for its novel NSCLC treatment, showing strong efficacy and potential for advanced lung cancer patients.

Discover how modern clinical trials are shifting focus toward immune-system dynamics to better treat multiple sclerosis and improve long-term patient care.

Piramal Pharma shares jumped 4% following a successful US FDA inspection. Learn how this regulatory milestone bolsters the company's global growth outlook.

Discover how Real-World Evidence is reshaping clinical trials and accelerating drug development by using patient data from outside traditional study settings.

AstraZeneca stock falls following a clinical trial failure. Get the latest analysis on the impact of this study and the firm’s future research outlook.